Mars is the world’s largest chocolate company and the maker of M&M’s and Snickers — yet pet care is now more than half its business, it runs the largest veterinary network in America, and it just borrowed roughly $26 billion to buy Pringles and Pop-Tarts[5][8][19].

With an estimated $54.6 billion in 2024 sales, Mars is one of the largest private companies on earth — owned entirely by the Mars family, run on its century-old “Five Principles,” and famous for telling the outside world almost nothing[26][31][34]. In December 2025 it closed the $36 billion acquisition of Kellanova, creating a ~$36B snacking arm with nine billion-dollar brands[15][18]. The decisive questions are whether the pet-care engine keeps outgrowing the candy, whether the debt-funded Kellanova bet pays off against antitrust and health headwinds, and whether a secretive family giant can keep expanding as regulators and public-health advocates push back. This study lays out both cases on each — and weighs them. The short version: the pet-care engine looks durable (high confidence), the Kellanova bet is strategically coherent but financially unproven — genuinely contested, because Mars discloses nothing that would settle it[34] — and the backlash is more likely to keep extracting reformulations than to break the model[37]. The full weighing, with what would flip each reading, closes Section 09.

The decisive questions

Each links to the section that lays out the evidence on both sides.

The business behind the candy wrapper

Estimated revenue mix by segment. Mars does not disclose segment figures; pet care is reliably reported as more than half of sales, with snacking next and a small food arm. Values are rounded estimates. Hover a slice.

Mars has been family-owned for over a century, headquartered in McLean, Virginia, and run on the Five Principles (Quality, Responsibility, Mutuality, Efficiency, Freedom)[2]. Two threads define it: a century-old confectionery heritage and a relentless expansion — into gum, pet food, veterinary care, and now Kellanova.

What Mars does

Mars, Incorporated is a private, family-owned company with more than $50 billion in annual sales and 140,000+ associates across three businesses: Pet Care (Royal Canin, Pedigree, Whiskas plus Mars Veterinary Health), Snacking (M&M’s, Snickers, Skittles and Wrigley gum, now joined by Kellanova), and a smaller Food & Nutrition arm (Ben’s Original, Dolmio)[3][6].

How it got here

The single most counter-intuitive fact about Mars: pet care is more than half of sales — bigger than all its chocolate and gum combined[5]. Mars is a pet-care company with a world-famous candy business attached, not the other way around.

The estimated revenue mix

Mars is private and does not break out segment revenue, so these shares are rounded estimates built from reporting that pet care is “more than half” of sales. Treat the exact splits as illustrative, not disclosed. Hover a slice.

The three businesses

Segment composition[6]; pet care >half of sales[5]; Mars Wrigley + Kellanova[7][15].

Mars runs the largest veterinary network in America — roughly 3,000 clinics including Banfield, BluePearl and VCA — on top of pet-food leaders Royal Canin and Pedigree[8]. That vertical integration is both the growth engine and the reason Mars draws antitrust and conflict-of-interest scrutiny[10][11].

The scale: bigger than Purina

Estimated pet-care revenue ($B). Mars Petcare — pet food plus veterinary services — is widely described as the world’s largest pet-care business, ahead of Nestlé’s ~$20B Purina. Both bars are estimates; Mars does not disclose segment revenue. Hover a bar.

Mars pet care >half of ~$55B sales (estimate)[5][26]; Nestlé Purina ~$20B[25].

How Mars built it

• Pet food. Royal Canin (acquired 2001, ~$730M) anchors the premium, vet-recommended end; Pedigree, Whiskas, Iams and Nutro span the mainstream. Mars is investing ~$2B in US pet-food capacity through 2026[9][13].
• Veterinary care. Banfield (~1,000 general hospitals, more than half inside PetSmart), BluePearl (specialty/ER), VCA, AniCura (Europe) and Linnaeus (UK) make Mars the largest vet provider in the US[8].
• Diagnostics & more. Mars also owns veterinary diagnostic labs and pet-tech, deepening its grip across the pet-health value chain[11].

The consolidation debate

The same vertical integration that powers growth is what critics attack. The 2017 VCA deal cleared the FTC only after Mars divested 12 clinics[10]. In November 2024, Senators Warren and Blumenthal opened an investigation, stating Mars Petcare owned nearly half of all corporate-owned vet clinics and asking whether it steers pet owners to Mars-owned labs and food and uses noncompetes — against a backdrop of US vet prices rising more than 60% in a decade[11]. Commentary in the veterinary profession frames it as the broader corporate consolidation of veterinary medicine[41][12]. Mars argues its scale funds better facilities, training and pet outcomes[9].

Mars bought Kellanova for ~$36 billion — its largest deal ever — funding it almost entirely with new debt and creating a ~$36B snacking business with nine billion-dollar brands[14][15][19]. US regulators waved it through; the EU warned it could raise food prices before clearing it[16][17].

The deal at a glance

The strategic logic

Kellanova brings salty snacks (Pringles, Cheez-It) and portable wholesome-ish snacking (Pop-Tarts, RXBAR, Eggo) that complement Mars’s chocolate and gum, plus international cereal. Combined, Mars’s snacking arm reaches roughly $36B in revenue with nine billion-dollar brands, giving it more shelf power and a broader snacking platform than chocolate alone could provide[15].

Two regulators, two verdicts

The US FTC granted early termination of its review in June 2025 with no conditions[16]. The EU went the other way, opening an in-depth probe over concerns that a larger Mars could squeeze retailers and push up prices on already-inflated grocery bills before granting final, unconditional approval on December 11, 2025[17][18]. The divergence reflects how much weight EU antitrust gives to retailer bargaining-power concerns[21].

What the price implies — three checkable ratios

Mars discloses little, but the deal terms allow some simple arithmetic (our division over the cited figures — illustrative, not company guidance). Price-to-sales: ~$35.9B over Kellanova’s ~$13B of 2023 net sales is roughly 2.8x revenue[14]. Debt-to-target: the ~$26B of bonds plus the $1B private placement and $4B term loan total ~$31B of new borrowing — about 2.4x Kellanova’s annual sales and roughly 57% of Mars’s entire ~$54.6B 2024 standalone revenue[19][26]. Consistency check: the stated ~$36B combined snacking arm minus Kellanova’s ~$13B implies legacy Mars snacking of ~$23B — about 42% of 2024 sales, consistent with the ~40% segment estimate used throughout this study[15][26]. The arithmetic frames the bet plainly: Mars borrowed more than twice the target’s yearly revenue to buy growth in its slower segment.

Mars is #1 in two markets at once: it leads the ~$130B global chocolate market (>12% share) and the ~$128B global pet-food market[22][24]. But the two move differently — pet care is growing ~6% a year, while chocolate is mature and increasingly health-pressured[24][20].

Confectionery: leader of a mature market

The global chocolate market was worth about $129.6 billion in 2025, led by Mars with over 12% share; the top five (Mars, Mondelez, Ferrero, Hershey, Nestlé) together held roughly 38%[22]. In the US, Hershey and Mars alone account for over 60% of confectionery[23]. It is a high-margin, brand-driven oligopoly — but growth is slow and the category faces sugar taxes, the ultra-processed-food backlash and anti-dye regulation[20][39].

Pet care: leader of a growth market

The global pet-food market was about $128 billion in 2024 and is projected to reach roughly $186 billion by 2030, a ~6.4% CAGR driven by pet ownership and premiumization — with Mars Petcare and Nestlé Purina the leading vendors[24]. Layered on top is veterinary care, where Mars is the largest US provider[8]. This is the faster-growing half of Mars’s portfolio.

Mars generated about $54.6 billion in 2024 sales — known only because a bond prospectus forced disclosure ahead of the Kellanova deal[26]. The model’s edge is private, long-term capital under the Five Principles; its new wrinkle is ~$26B of debt[43][19].

How Mars makes money

Mars sells branded pet food and vet services, branded confectionery and gum, and packaged food — overwhelmingly through retail and, in pet care, through its own clinics. Pet care (more than half of sales) is the largest profit engine; confectionery is a high-margin cash cow[5][27]. Because Mars is private, it discloses no segment profit, margins or cash flow — the figures below are the rare knowable points.

The balance-sheet shift

For most of its history Mars funded itself from cash flow and carried little debt. The Kellanova acquisition changed that: Mars raised roughly $26 billion in bonds (plus a private placement and a term loan) to replace a $29B bridge loan[19][28]. For a company that prizes financial independence, taking on the biggest US bond deal of the year is a meaningful strategic change — and a bet that snacking scale will service the debt comfortably.

The expectations read — what bar is Mars measured against?

Mars has no share price, no funding rounds and no planned exit — the “Freedom” principle explicitly commits it to staying private[43]. The closest external markers of value: the family fortune is estimated above $126 billion[32], which against ~$54.6B of 2024 sales implies a rough ~2.3x-revenue valuation (our division of two reported estimates — illustrative only)[26], and Mars itself paid ~2.8x sales for Kellanova[14]. With no public shareholders, the binding outside constituency is now bondholders: the ~$26B bond stack must be serviced by a snacking arm in a mature category while pet care still absorbs growth capex (~$2B committed to US pet-food capacity alone)[19][22][13]. That is the bar both bull and bear are measured against — not a stock multiple, but whether future bond disclosures show the leverage coming down without the growth engine being starved.

Mars faces Mondelez, Ferrero, Hershey and Nestlé in chocolate and Nestlé Purina, Hill’s and General Mills in pet food — concentrated markets, not price wars[29][30]. The sharper lens is internal: pet care is the star, confectionery the cash cow.

Who Mars competes with

• Confectionery: Mondelez (Cadbury, Toblerone), Ferrero (Nutella, Kinder), Hershey, Nestlé — the top five hold ~38% of global chocolate, with Mars on top[22][29].
• Pet food: Nestlé Purina (~$20B), Hill’s Pet Nutrition (Colgate-Palmolive), General Mills (Blue Buffalo), J.M. Smucker[30].
• Veterinary care: JAB-backed chains (NVA, Compassion-First) and a long tail of independents — the arena drawing antitrust attention[11].
• Salty snacks (post-Kellanova): PepsiCo’s Frito-Lay and Mondelez, where Pringles and Cheez-It now compete[15].

Five Forces: stable, but pressured at the edges

Click a force to see the rated pressure and the evidence. Buyer power (concentrated retailers) and supplier power (cocoa) bind hardest; brand and scale moats keep new entrants out; substitutes are a growing health-driven pressure on confectionery.

The portfolio view (BCG)

Mars’s three segments mapped on market position (challenger → leader) and category growth (mature → high growth). Pet care is the rare combination of leadership and growth; confectionery is a leading but mature cash cow; Food & Nutrition is small. Hover a point for the sourced basis.

The Mars family owns 100% of the company — Jacqueline and John Mars each hold roughly a third — a fortune estimated above $126 billion[31][32]. Professional managers run it day to day under CEO Poul Weihrauch; the family sets the long horizon and the secrecy[33][34].

Who owns Mars

Mars is owned entirely through family trusts descended from founder Frank Mars. Third-generation siblings Jacqueline and John Mars each hold about a third, with the remaining third split among the heirs of the late Forrest Mars Jr.[31]. Forbes pegs Jacqueline Mars’s net worth around $38–39 billion; the family’s combined fortune is estimated above $126 billion, among the largest in the world[32].

The Five Principles and professional management

Mars runs on its Five Principles — Quality, Responsibility, Mutuality, Efficiency, Freedom — codified under Forrest Mars Sr.[2]. The family largely stepped back from day-to-day operations, handing the company to professional executives; Poul Weihrauch has been CEO since 2022, steering the Kellanova deal and a record-revenue era[33]. “Freedom” in the principles is explicit about staying private to keep that independence[43].

Succession and continuity

With the third generation now elderly, ownership is passing to a widening fourth and fifth generation. Mars has managed this before — the company was reunited and professionalized across generations — but multi-branch family ownership at this scale is itself a long-run governance question, especially as the company takes on debt and expands[31][19].

The scale-and-shape table

Mars ~$54.6B (est.)[26]; Nestlé Purina ~$20B[25]; Kellanova ~$13B (2023)[14]; chocolate-market leaders[29]. Mondelez, Hershey and Ferrero figures are widely-reported approximate group revenues for scale context, not Mars-sourced.

What makes Mars different

• It’s private. Among the global food leaders, only Mars and Ferrero are family-private; the rest answer to public shareholders[31].
• It’s a pet company in disguise. No other major confectioner derives most of its revenue from pet care and vet services[5][8].
• It just got bigger in snacking. Kellanova moves Mars decisively into salty snacks against PepsiCo and Mondelez[15].

How to read the field

On scale Mars sits in the top tier of global food, below all-of-Nestlé but ahead of Mondelez and far ahead of Hershey. Its distinctiveness is structural, not size: private control and a pet-care-led portfolio. Whether that shape is an advantage (diversified, patient, growth-tilted) or a liability (opaque, leveraged, health-exposed) is the question the rest of this study weighs[24][20].

Mars is broadly admired as a brand and employer (TIME World’s Best Companies 2025) yet faces a stack of concurrent controversies: cocoa child-labor litigation, food-dye regulation, ultra-processed scrutiny, and a Senate probe into vet-care consolidation[4][35][39][11]. None is fatal alone; together they shape the regulatory weather.

The controversy stack

• Cocoa & child labor. In February 2021, eight formerly trafficked Malian children sued Mars (alongside Nestlé, Cargill, Mondelez, Hershey, Olam and Barry Callebaut) in US federal court — Coubaly v. Cargill — alleging the companies knowingly benefited from forced child labor on Côte d’Ivoire cocoa farms under the Trafficking Victims Protection Reauthorization Act[35][45]. The suit was dismissed for lack of standing, and the D.C. Circuit affirmed on 22 July 2025[45]. Mars says it “unequivocally condemns” child labor and funds eradication programs[35].
• Food dyes. Mars pledged in 2016 to remove artificial colors, then kept synthetic dyes in US products (while removing them in Europe). Under 2025 MAHA/FDA pressure it announced dye-free versions; Texas’s AG issued a civil investigative demand[38][39][40].
• Titanium dioxide. A 2022 suit called Skittles “unfit for human consumption” over TiO2; Mars said it complied with FDA rules and later removed TiO2 from US Skittles[36][37].
• Ultra-processed foods. Critics note ~74% of Mars’s and 78% of Kellanova’s products are ultra-processed, arguing the merger concentrates UPF amid a health backlash[20].
• Vet-care consolidation. A Senate probe and FTC history question whether Mars’s vet dominance raises pet-owner costs[11][10].

SWOT — even-handed

Each SWOT item is sourced in the section it draws from; see the Sources list.

The weighing

On whether Mars is a candy company or a pet company: the evidence leans pet company — and toward the pet engine staying the growth engine (high confidence on the mix, medium on the trajectory). The controlling evidence is that pet care is already more than half of sales[5] and that its market is projected to grow from ~$128B to ~$186B by 2030 (~6.4% a year)[24], which outweighs the brand-fame counter because revenue mix, not shelf recognition, is what compounds. The strongest surviving counter-argument: the vet network’s expansion path is narrowing — the FTC already forced clinic divestitures in 2017[10] and the Senate probe signals that acquisition-led US vet growth is largely closed[11]. What would flip this reading: pet-food market growth revised materially below ~6% in the next major industry forecast update[24], or the Senate/FTC inquiry producing an enforcement action that forces clinic divestitures at scale. Pre-mortem: if this looks wrong in two years, the most likely reason is vet-price backlash hardening into regulation that caps the services business — or, on the other side, pet-care growth proving even stronger and the candy framing of Mars simply expiring.

On whether the $36B Kellanova bet was worth it: the evidence is genuinely contested (contested confidence) — strategically coherent, financially unproven. The evidence that deadlocks it: the deal verifiably built a ~$36B snacking arm with nine billion-dollar brands and cleared both regulators[15][18], but it loaded ~$31B of new borrowing onto a previously near-unlevered company[19][28] — and the one number that would settle the question, combined snacking margin and cash flow, is undisclosed because Mars is private[34]. The strongest bull argument: Mars has absorbed transformative deals before — Wrigley in 2008, VCA in 2017[7][10]. The strongest bear argument: ~74% of Mars’s and ~78% of Kellanova’s products are ultra-processed, so the deal concentrates exposure to exactly the backlash now gathering[20]. What would flip this reading: the revenue and leverage figures in Mars’s next bond-investor disclosure — the channel that revealed the $54.6B figure[26] — showing debt paydown running ahead of or behind the bond schedule; the divestiture of any major Kellanova brand would be the bear tell. Pre-mortem: if this looks wrong in two years, the most likely reason is interest burden and integration costs compounding while snacking stagnates — or, on the other side, shelf-power synergies arriving faster than the ultra-processed fears.

On whether family ownership is a strength or a shield: the evidence leans both-at-once, with the strategic benefit currently dominating (medium confidence). The controlling evidence is the record of patient bets that verifiably built two #1 positions — Royal Canin in 2001, VCA in 2017, Kellanova in 2025[9][10][14] — which outweighs the opacity critique because the diversification actually happened while public rivals stayed in their lanes. The strongest surviving counter-argument: the accountability gap is documented, not hypothetical — senators had to open an investigation to ask basic questions about pricing and steering[11], and the only firm revenue figure exists because bondholders forced its disclosure[26]. What would flip this reading: a fourth-/fifth-generation ownership dispute or liquidity event forcing restructuring as the elderly third generation exits[31], or a regulatory finding that the opacity concealed consumer harm. Pre-mortem: if this looks wrong in two years, the most likely reason is succession friction surfacing — or, on the other side, the new debt quietly disciplining Mars into more disclosure than its critics expected.

On whether Mars can outrun the health and antitrust backlash: the evidence leans yes on adaptation, no on escape (medium confidence). The controlling evidence is Mars’s consistent pattern of reformulating under pressure — titanium dioxide out of US Skittles[37], dye-free lines under FDA/MAHA pressure[38][40] — plus the cocoa child-labor suit’s dismissal being affirmed on appeal in July 2025[45], which outweighs the existential reading because every backlash so far has ended in a product change, not structural damage. The strongest surviving counter-argument: the ultra-processed critique attacks the category, not an ingredient — ~74% of the portfolio cannot be reformulated away, and Kellanova increased that exposure[20]. What would flip this reading: a federal ultra-processed-food labeling or marketing restriction moving from rhetoric to rulemaking; the Texas AG’s civil investigative demand[39] or the Senate vet-care probe[11] escalating into enforcement with structural remedies. Pre-mortem: if this looks wrong in two years, the most likely reason is underestimating how fast ultra-processed policy hardens — or, on the other side, overweighting a backlash that consumers, still buying, never joined.

None of this is a recommendation — Mars has no stock to buy. It is a reading of where the documented evidence points, and each paragraph above names the data that would change it.

Method

Research proceeded by fan-out web search and direct fetching of primary and reputable secondary sources — Mars’s own corporate releases and history pages, US regulatory primary sources (FTC orders and statements, a US Senate investigation letter), the public filings and coverage of Kellanova (an SEC registrant), reputable business and trade press (Fortune via Yahoo Finance, CNBC, Washington Post, Crain’s, BNN Bloomberg, FoodNavigator, BakeryAndSnacks, New Food Magazine, STAT), market researchers (Global Market Insights, Expert Market Research, ResearchAndMarkets), and reference works (Britannica, Wikipedia) for dated history. Every URL cited was opened and read during the run; each claim was transcribed into a structured manifest tagging it with a tier (1 = primary/official, 2 = reputable secondary, 3 = aggregator/soft), a confidence level, and a stance (supporting / critical / neutral). Mars is a US-based, English-language company, so no native-language research pass was required.

The private-company caveat (read this first)

Mars is privately held and discloses almost no financial detail. There is no annual report, no segment P&L, no audited revenue breakdown. Consequently, every revenue, segment-share and market-share figure in this study is an estimate — drawn from a bond prospectus (the ~$54.6B 2024 sales figure), market-research reports, or press reporting (e.g. “pet care is more than half of sales”). The segment-mix donut (~55/40/5) is a rounded illustration, not a disclosed split. Treat all such numbers as directional.

Frameworks used

The analysis applies the Pyramid Principle (an answer-first executive summary), a BCG-style portfolio map (market position vs. category growth) to locate Mars’s three segments, Porter’s Five Forces on its branded-food and pet-care markets, peer comparables on scale and structure, and a SWOT — each applied even-handedly, with high-pressure forces and risks given the same weight as strengths. No discounted-cash-flow valuation was attempted: with no disclosed margins, segment profit or cash flow, the inputs simply do not exist for an outside analyst.

Neutrality & independence

Each section pairs the case for Mars against the case against it, positive and critical claims alike are attributed to their sources, and the closing weighing states where the evidence leans, at what confidence, and what would change each reading — a weighed reading, not a recommendation. The study is an independent research artifact, not affiliated with, sponsored by, or endorsed by Mars, Incorporated, Kellanova, or any company or official named here, and it is not investment advice — no rating, price target, or recommendation to buy or sell any security. It is point-in-time as of 7 June 2026, and corrections are welcome.

Cross-checked at build time by an automated link checker. Because Mars is privately held, revenue, segment-share, market-share and peer figures are reported estimates and are labeled throughout and in Methodology & Limits.